Bismuth subcitrate potassium

DB09275ApprovedInvestigationalSmall molecule

Bismuth subcitrate potassium is a colloid used for the treatment of peptic ulcer and gastro-esophageal reflux disease (GERD). A medication used to treat digestive disorders associated with open sores and heartburn.

Chemical structure of Bismuth subcitrate potassium
Mechanism
Curator reviewed
Primary indication
For the treatment of peptic ulcer and gastro-oesophageal reflux disease (GORD).Curator reviewed · 11 structured indications
Formula / weight
C12H8BiK5O14 · 780.654 g/mol (avg)
First approval
Canada, 2023 · United States, 2007
Brand names
  • Pylera

Resolves to

Clinical / RWD
Structure
InChIKeyYDDTTXDPCSCLKY-UHFFFAOYSA-HSMILES[K+].[K+].[K+].[K+].[K+].[Bi+3].[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O.[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O
Targets

What you can answer from here — as of August 30, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
155Drug interactionsStructured to mechanism, not free text
Sign in
30Clinical trialsPhase, status and sponsor resolved per trial
Sign in
11Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
5ContraindicationsEach with its own population and attribute set
Sign in
54Marketed productsAcross 5 countries and 26 labellers
Sign in
5+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Bismuth subcitrate potassium, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account